Primary navigation

    DPP-4 inhibitors

    Drug  - DPP-4 inhibitors (Kazano®, Nesina®, Oseni®) [Takeda]

    October 2013

    Therapeutic area - Antihyperglycemics

    Approval criteria

    • Patient has a diagnosis of Type 2 diabetes AND
    • Patient has tried metformin (alone or in combination) or has a contraindication to metformin AND
    • Patient has tried a sulfonylurea (alone or in combination) or has a contraindication to sulfonylureas AND
    • Patient has tried a preferred DPP-4 inhibitor

    Quantity limit

    Kazano®: quantity limit is 68 tablets per 34-day supply
    Nesina®: quantity limit is 34 tablets per 34-day supply
    Oseni®: quantity limit is 34 tablets per 34-day supply

    Background information

    DPP-4 inhibitors are indicated as an adjunct to diet and exercise to improve glycemic control in patients with Type 2 diabetes.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top